T1D RELAY
- Study HIC#:2000025525
- Last Updated:09/04/2024
TrialNet is studying the use of rituximab-pvvr and abatacept, one after the other, to learn if using both treatments extends insulin production in people newly diagnosed with type 1 diabetes (T1D).
Previous studies with similar treatments showed people can make more insulin for a longer period of time while receiving either of the treatments. T1D RELAY will study if two treatments consecutively performs better than rituximab-pvvr alone. Researchers will test if those who are also treated with abatacept have better C-peptide levels over time.
- Age8 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Marcia DeSousa at The Yale Pediatric Diabetes Program
- Phone Number: 1-203-737-4805
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
This study is enrolling children and adults who are:
- Age 8-45
- Newly diagnosed with T1D (in past 3 months)
AND have:
- 1 or more diabetes-related autoantibodies
- C-peptide detectable during a mixed-meal tolerance test (MMTT)
